Lived Experience of Advanced Hybrid Closed-Loop Versus Hybrid Closed-Loop: Patient-Reported Outcomes and Perspectives.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Mary Ann Liebert, Inc Country of Publication: United States NLM ID: 100889084 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-8593 (Electronic) Linking ISSN: 15209156 NLM ISO Abbreviation: Diabetes Technol Ther Subsets: MEDLINE
    • Publication Information:
      Original Publication: Larchmont, NY : Mary Ann Liebert, Inc., c1999-
    • Subject Terms:
      Blood Glucose Self-Monitoring* ; Diabetes Mellitus, Type 1*/drug therapy; Adolescent ; Blood Glucose ; Humans ; Hypoglycemic Agents/therapeutic use ; Insulin/therapeutic use ; Insulin Infusion Systems ; Patient Reported Outcome Measures ; Young Adult
    • Abstract:
      This article reports on the lived experience of Medtronic advanced hybrid closed-loop (AHCL) in comparison to first generation hybrid closed-loop (HCL) in a randomized, open-label, two-period crossover trial. Patient-reported outcome (PROs) measures were administered before randomization and at the end of each study period in 113 adolescents and young adults with type 1 diabetes. Glucose monitoring satisfaction subscales for emotional burden and behavioral burden improved significantly ( P  < 0.01) over time with use of AHCL versus HCL and co-occurred with glycemic improvements (reduced percent time above 180 mg/dL during the day and no change in % time less than 54 mg/dL across 24 h) and greater time in Auto Mode. PROs, including distress, technology attitudes, and hypoglycemia confidence, were not different. AHCL use was associated with improved glucose monitoring satisfaction. Satisfaction was greater in those participants who had more appreciable glycemic benefit and stayed in Auto Mode more often. Clinical Trial Registration number: NCT03040414.
    • References:
      Diabet Med. 2019 May;36(5):644-652. (PMID: 30761592)
      Diabetes Care. 2018 Aug;41(8):1623-1630. (PMID: 29921624)
      Diabetes Technol Ther. 2017 Feb;19(2):131-136. (PMID: 27997217)
      Diabetes Technol Ther. 2021 May;23(5):323-331. (PMID: 33252264)
      Diabetes Care. 2018 Sep;41(9):1862-1869. (PMID: 29976567)
      Lancet. 2021 Jan 16;397(10270):208-219. (PMID: 33453783)
      J Diabetes Sci Technol. 2016 Jun 28;10(4):852-8. (PMID: 27234809)
      Diabetes Res Clin Pract. 2013 Feb;99(2):174-84. (PMID: 23273515)
      Endocrinol Diabetes Metab. 2018 Feb 14;1(2):e00013. (PMID: 30815549)
      J Diabetes Sci Technol. 2019 Nov;13(6):1135-1141. (PMID: 30854886)
      Diabetes Technol Ther. 2015 Sep;17(9):657-63. (PMID: 25923812)
      Endocr Rev. 2019 Dec 1;40(6):1521-1546. (PMID: 31276160)
      Diabetes Care. 2005 Mar;28(3):626-31. (PMID: 15735199)
      Diabetes Care. 2010 May;33(5):1072-6. (PMID: 20150292)
      Lancet Digit Health. 2020 Feb;2(2):e64-e73. (PMID: 32864597)
      Diabetes Technol Ther. 2021 Mar;23(3):195-202. (PMID: 32991199)
    • Grant Information:
      P30 DK036836 United States DK NIDDK NIH HHS
    • Contributed Indexing:
      Keywords: Adolescents; Automated insulin delivery; Closed loop; Patient-reported outcomes; Type 1 diabetes; Young adults
    • Molecular Sequence:
      ClinicalTrials.gov NCT03040414
    • Accession Number:
      0 (Blood Glucose)
      0 (Hypoglycemic Agents)
      0 (Insulin)
    • Publication Date:
      Date Created: 20210716 Date Completed: 20220328 Latest Revision: 20221202
    • Publication Date:
      20240105
    • Accession Number:
      PMC9009590
    • Accession Number:
      10.1089/dia.2021.0153
    • Accession Number:
      34270328